Efficacy and Safety of Nerandomilast in Patients with Autoimmune-Interstitial Lung Disease (ILD) and Progressive Pulmonary Fibrosis in Subgroups by Time Since ILD Diagnosis (ACR Convergence 2026) - Sep 8, 2026 - Abstract #1617; Pres time: Nov 9, 2026; 10:30 AM - 12:30 PM; Location: WB1&2; In Person; "At baseline, nintedanib was taken by 34.2% and immunosuppressant therapy by 55.1% of patients. In the FIBRONEER-ILD trial in patients with PPF, the effect of nerandomilast on slowing ILD progression in patients with autoimmune ILD was consistent across subgroups by time since diagnosis of ILD."
Clinical • Immunology • Inflammatory Arthritis • Interstitial Lung Disease • Pulmonary Disease • Respiratory Diseases • Rheumatoid Arthritis • Scleroderma • Systemic Sclerosis
|
|
Madelon Vonk 1; Cosimo Bruni 2; Elana Bernstein 3; Jing Xue 4; Masataka Kuwana 5; Daniel Wachtlin 6; Patrick Hofmann 7; Donald Zoz 8; and Shervin Assassi 9
|